Publications by authors named "M Faggen"

Claim this Profile
T
TRADE: a phase II trial to assess the tolerability of abemaciclib dose escalation in early-stage HR-positive/HER2-negative breast cancer.
E L Mayer, D Trapani, S-E Kim, M Faggen, N Sinclair

Ann Oncol· January 2026

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Video Education Is an Acceptable Alternative to Pretest Genetic Counseling for Patients With Breast, Ovarian, Pancreatic, and Metastatic Prostate Cancer: Results From a Randomized Study.
Katherine A Schneider, Lauren Massingham, Michelle Weitz, Chanika Phornphutkul, Melissa Leach, Meredith Faggen

JCO Oncol Pract· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Axillary Management and Outcomes After Neoadjuvant Endocrine Therapy in the Randomized PELOPS Trial.
Anna Weiss, Qingchun Jin, Nabihah Tayob, Eileen Wrabel, Michelle DeMeo, Meredith Faggen

Ann Surg Oncol· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Subcutaneous vs Intravenous Trastuzumab/Pertuzumab: A Time and Motion Substudy of a Phase II Trial of Adjuvant Trastuzumab/Pertuzumab for Stage I HER2+ Breast Cancer (ADEPT trial).
Adrienne G Waks, Emily L Chen, Noah Graham, Anna Mae Frey, Kenneth Almeida, Meredith Faggen

JCO Oncol Pract· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Shared Local Oncology Care After Allogeneic Hematopoietic Cell Transplantation: A Randomized Clinical Trial.
Gregory A Abel, Haesook T Kim, Ira Zackon, Edwin T Alyea, Alexandra S Bailey, Meredith A Faggen

JAMA Oncol· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis